


**Step 1 Patient Information**

\*First name: \_\_\_\_\_ \*Last name: \_\_\_\_\_  
 \*Date of birth (MM/DD/YYYY): \_\_\_\_ / \_\_\_\_ / \_\_\_\_ Gender:  Male  Female  
 Street: \_\_\_\_\_ Apt: \_\_\_\_\_  
 City: \_\_\_\_\_ \*State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
 Home phone: (\_\_\_\_) \_\_\_\_ - \_\_\_\_ Cell phone: (\_\_\_\_) \_\_\_\_ - \_\_\_\_  Do not contact patient  
 Email: \_\_\_\_\_ Preferred language:  English  Spanish  Other: \_\_\_\_\_  
 Alternate contact name: \_\_\_\_\_ Relationship: \_\_\_\_\_ Alt. phone: (\_\_\_\_) \_\_\_\_ - \_\_\_\_

**Step 2 Insurance Information** Is the patient insured?  Yes  No Has the patient started therapy?  Yes  No

 **If the patient is uninsured, please complete the Genentech Patient Foundation Enrollment Form or call (888) 941-3331 for assistance. If insured, please fill out the information below or attach a copy of the patient's insurance cards.**

Is prior authorization in place?  Yes  No Auth #: \_\_\_\_\_

	Primary Insurance	Secondary Insurance	Pharmacy Benefit
Insurance name			
Subscriber name (if not patient)			
Subscriber/Policy ID #			
Group #			
Insurance phone			

**Step 3 Diagnosis and Clinical Information (Complete to the highest level of specificity for diagnosis codes.)**

<p><b>IgE-mediated Food Allergy</b></p> <input type="checkbox"/> Z91.010 Allergy to peanuts <input type="checkbox"/> Z91.011 Allergy to milk products <input type="checkbox"/> Z91.012 Allergy to eggs <input type="checkbox"/> Z91.013 Allergy to seafood <input type="checkbox"/> Z91.018 Allergy to other foods	<p><b>Chronic Spontaneous Urticaria (CSU)</b></p> <input type="checkbox"/> L50.0 Allergic urticaria <input type="checkbox"/> L50.1 Idiopathic urticaria <input type="checkbox"/> L50.8 Other (chronic, recurrent) urticaria <input type="checkbox"/> L50.9 Urticaria, unspecified	<p><b>Allergic Asthma</b></p> <input type="checkbox"/> J45.40 Moderate persistent asthma, uncomplicated <input type="checkbox"/> J45.50 Severe persistent asthma, uncomplicated	<p><b>Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)</b></p> <input type="checkbox"/> J33.0 Polyp of nasal cavity <input type="checkbox"/> J33.1 Polypoid sinus degeneration <input type="checkbox"/> J33.8 Other polyp of sinus <input type="checkbox"/> J33.9 Nasal polyp, unspecified
--	--	--	--

Other diagnosis code: \_\_\_\_\_

**Step 4 Acquisition and Administration Information**

Dispense XOLAIR:  Autoinjector (≥12 years old)  Prefilled Syringe  Vial Dispensing of XOLAIR through:  Specialty pharmacy  Buy and bill  
 Anticipated date of treatment: \_\_\_\_ / \_\_\_\_ / \_\_\_\_ Preferred specialty pharmacy: \_\_\_\_\_  
 Place of administration/ship to:  Physician's office  HOPD  Alternate injection center  Patient's address  
 Place of administration name: \_\_\_\_\_ Place of administration tax ID #: \_\_\_\_\_  
 Street: \_\_\_\_\_ Suite: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

**Step 5 XOLAIR Co-pay Program Enrollment Criteria**

- By checking this box, I certify that:
- I have the patient's consent to enroll in the Genentech XOLAIR Co-pay Program for assistance with drug out-of-pocket costs and/or Genentech XOLAIR administration out-of-pocket costs
  - The patient is not using and I will not bill any federal- or state-funded health care program. This includes, but is not limited to, Medicare, Medicaid, Medigap, VA, DoD and TRICARE
  - The patient is not currently receiving Genentech XOLAIR from the Genentech Patient Foundation
  - The patient is not currently receiving assistance from any other charitable organization for any of their out-of-pocket costs that are covered by the Genentech XOLAIR Co-pay Program
  - I have read and accepted the full Program Terms and Conditions as found at [XOLAIRcopay.com/terms-and-conditions](http://XOLAIRcopay.com/terms-and-conditions)
  - Genentech reserves the right to rescind, revoke or amend the program without notice at any time

for **XOLAIR**<sup>®</sup>  
(omalizumab) for subcutaneous use

**SUBMIT ONLY REQUESTED DOCUMENTS**

Required field (\*) M-US-00012226(v5.0) 03/24

**Step 6 Patient Information (please re-enter)**

\*First name: \_\_\_\_\_ \*Last name: \_\_\_\_\_ \*Date of birth (MM/DD/YYYY): \_\_\_\_/\_\_\_\_/\_\_\_\_

**Step 7 Prescriber Information**

\*First name: \_\_\_\_\_ \*Last name: \_\_\_\_\_

\*Practice name: \_\_\_\_\_

\*Street: \_\_\_\_\_ Suite: \_\_\_\_\_

\*City: \_\_\_\_\_ \*State: \_\_\_\_\_ \*ZIP: \_\_\_\_\_

Prescriber tax ID #: \_\_\_\_\_ Prescriber NPI #: \_\_\_\_\_ Group NPI #: \_\_\_\_\_

Office contact: \_\_\_\_\_ Contact phone: (\_\_\_\_) \_\_\_\_-\_\_\_\_ Contact fax: (\_\_\_\_) \_\_\_\_-\_\_\_\_

If you are a resident of a US state that provides certain rights with respect to your personal information, a complete description of the personal information we may collect and process, the purposes for which it is used by Genentech, and your rights under your state's privacy laws concerning your personal information can be found in our privacy notice at [www.gene.com/privacy-policy](http://www.gene.com/privacy-policy).

**Complete steps 8-10 ONLY if you are requesting the XOLAIR Starter Program. Signature and date are required at the bottom for this program only.**

**Step 8 XOLAIR Starter Program (Prescriber signature required. Check all relevant boxes.)**

XOLAIR Starter Program supplies the first 30 days of medicine. If coverage decision is delayed past 3 weeks, we will follow up for 1 refill. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. For full eligibility criteria and Terms and Conditions, please visit [www.Genentech-pro.com/starter](http://www.Genentech-pro.com/starter) or speak to your Genentech representative.

**IgE-mediated Food Allergy**

Clinical history consistent with IgE-mediated food allergy

Positive specific IgE and/or positive skin prick test and/or Oral Food Challenge to allergenic food(s)

Pretreatment serum IgE level IU/mL (1.0 kU/L=1.0 IU/mL; 2.4 ng/mL=1.0 IU/mL):

IgE level: \_\_\_\_\_ Patient weight: \_\_\_\_\_ kg

**Chronic Spontaneous Urticaria (CSU)**

Other CSU therapies:  H1 antihistamine

**Allergic Asthma**

History of positive skin or RAST test to a perennial aeroallergen

Symptoms inadequately controlled with inhaled corticosteroids (ICS)

Pretreatment serum IgE level IU/mL (1.0 kU/L=1.0 IU/mL; 2.4 ng/mL=1.0 IU/mL):

IgE level: \_\_\_\_\_ Patient weight: \_\_\_\_\_ kg

**Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)**

Patient has inadequate response to nasal corticosteroids

Pretreatment serum IgE level IU/mL (1.0 kU/L=1.0 IU/mL; 2.4 ng/mL=1.0 IU/mL):

IgE level: \_\_\_\_\_ Patient weight: \_\_\_\_\_ kg

Other: \_\_\_\_\_

**Step 9 Prescription Information**

Prescription type:  Naïve/new start

Restart

Last injection date (if applicable): \_\_\_\_/\_\_\_\_/\_\_\_\_

Dispense XOLAIR:  Autoinjector (≥12 years old)

Prefilled Syringe

Vial

\*Quantity dispensed:  30-day supply

90-day supply

Refill: \_\_\_\_\_ times

Prescription: (Please check dosage and frequency)

FREQUENCY	Every 2 weeks				Every 4 weeks		
MG/DOSE:	<input type="checkbox"/> 150	<input type="checkbox"/> 225	<input type="checkbox"/> 300	<input type="checkbox"/> 375	<input type="checkbox"/> 75	<input type="checkbox"/> 150	<input type="checkbox"/> 225
	<input type="checkbox"/> 450	<input type="checkbox"/> 525	<input type="checkbox"/> 600		<input type="checkbox"/> 300	<input type="checkbox"/> 450	<input type="checkbox"/> 600

**Step 10 Health Care Provider Certification**

**By submitting this form, I certify:** (a) The above therapy is medically necessary for this patient and the treatment decision has been made by the prescribing physician. (b) If the indication for which this Genentech product is being prescribed to treat is not listed in the FDA-approved label, the prescriber is prescribing the medication for an "unapproved" use, meaning that the FDA has not approved the efficacy, dosage amount or safety of this medication for such a use. (c) The provider's office received the authorization to release the information above and other protected health information (as defined by the Health Insurance Portability and Accountability Act of 1996 [HIPAA]) to Genentech, Inc., Genentech Access Solutions, the contracted dispensing pharmacy, or other contractors for the purpose of requesting reimbursement support, assisting in initiating or continuing therapy, as a break in treatment would negatively impact the patient's therapeutic outcome. (d) The provider's office will not attempt to seek reimbursement for free product provided to the patient. (e) The services requested on behalf of the patient may include benefits investigation (BI), prior authorization (PA) and appeals support, co-pay program referral or enrollment and co-pay assistance foundation referral. (f) **No action on these services will be taken until the patient consent document has been received.**

Sign, date and fax to **(800) 704-6612** \*Prescriber's Signature: \_\_\_\_\_ \*Date: \_\_\_\_/\_\_\_\_/\_\_\_\_  
(Original or stamped signature required)

FDA=US Food and Drug Administration; IgE=immunoglobulin E; NPI=National Provider Identifier; RAST=radioallergosorbent test.

XOLAIR is a registered trademark of Novartis AG.

©2024 Genentech USA, Inc. and Novartis Pharmaceuticals Corporation. All rights reserved. Printed in USA.

Phone: (800) 704-6610 | Fax: (800) 704-6612 | [Genentech-Access.com/XOLAIR](http://Genentech-Access.com/XOLAIR) | M-US-00012226(v5.0) | 03/24